- Home
- XRN vs AUTL Comparison
XRN vs AUTL Comparison
Compare XRN & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XRN | AUTL |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United Kingdom |
| Employees | 30 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 476.6M | 431.2M |
| IPO Year | 2016 | 2025 |
Fundamental Metrics
Financial Performance| Metric | XRN | AUTL |
|---|---|---|
| Price | $32.64 | $1.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 158.1K | ★ 1.4M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 8.74% | N/A |
| EPS Growth | N/A | ★ 28.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | $3.50 | $669.62 |
| Revenue Next Year | $3.13 | $79.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $33.29 | $1.11 |
| 52 Week High | $37.46 | $2.70 |
Technical Indicators
Market Signals| Indicator | XRN | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 29.70 | 38.42 |
| Support Level | N/A | $1.27 |
| Resistance Level | $37.18 | $1.52 |
| Average True Range (ATR) | 1.19 | 0.08 |
| MACD | -0.24 | -0.03 |
| Stochastic Oscillator | 0.00 | 1.43 |
Price Performance
Historical ComparisonAbout XRN Chiron Real Estate Inc. Common Stock
Chiron Real Estate Inc is a real estate investment trust focused on investing and actively managing critical healthcare infrastructure. Its portfolio includes Spectrum-Dumfries, Slippery Rock MOB, Gainesville Eye Center, Aurora Sports Health, and many Others. Geographically, the company has it's concentration in a small number of states, including Texas, Florida, Ohio, Arizona, Pennsylvania, and Illinois.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.